(-)-Deprenyl, A Selective MAO-B Inhibitor, with Apoptotic and Anti-apoptotic Properties

NeuroToxicology

Volumn 25, Issue 1-2, 2004, Pages 233-242

  Magyar, Kálmán ^a   Szende, Béla ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

( ) Deprenyl; Anti apoptotic activity; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIOXIDANT; ANTIPARKINSON AGENT; APOPTOSIS INDUCING FACTOR; APOPTOSIS INHIBITOR; CLORGYLINE; DESIPRAMINE; DOPAMINE; DOPAMINE DERIVATIVE; ENZYME INHIBITOR; ETHYLCHOLINE MUSTARD AZIRIDINIUM; LEVODOPA; MAZINDOL; METHAMPHETAMINE; MOFEGILINE; MONOAMINE OXIDASE B INHIBITOR; N 2 HEXYL N METHYLPROPARGYLAMINE; NEUROTOXIN; NORADRENALIN; RASAGILINE; SELEGILINE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL PROTECTION; CELL SURVIVAL; CLINICAL TRIAL; CONFUSION; DEMETHYLATION; DIZZINESS; DOPAMINE METABOLISM; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; DRUG URINE LEVEL; ENZYME INHIBITION; FIRST PASS EFFECT; GENE EXPRESSION; HALLUCINATION; HUMAN; INSOMNIA; LIMBIC SYSTEM; LOW DRUG DOSE; MELANOCYTE; MOTOR CONTROL; NAUSEA; NERVE CELL LESION; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW;

GYMNOMYZA SAMOENSIS; PARKINSONIA;

EID: 0346728595     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(03)00102-5     Document Type: Article

References (57)

1. Ansari KS, Zhang F, Holland DH, Yu PH, Tatton WG. R(-)-Deprenyl, not its major metabolites, rescue axotomized immature facial motoneurons. Soc Neurosci 1993;19:243 (Abstract).
2. Baumgarten HG, Zimmermann G. Selective neurotoxicity. In: Herken H, Hucho F, editors. Handbook of experimental pharmacy, vol. 102. Berlin: Springer-Verlag; 1992. p. 225-92.
3. Berry MD, Juono AV, Paterson IA. Possible mechanism of action of (-)-deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Neurobiology 1994;44:141-61.
4. Birkmayer W, Riederer P, Ambrozi L, Youdim MB. Implications of combined treatment with Madopar and L-deprenyl in Parkinson's disease. A long-term study. Lancet 1977;1(8009): 439-43.
5. Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J Neural Transm 1985;64(2):113-27.
6. Carrillo MC, Kanai S, Nokubo M, Kitani K. (-)-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 1991;48:517-21.
7. Carrillo MC, Kitani K, Kanai S, Sato Y, Ivy GO. The ability of (-)-deprenyl to increase superoxide dismutase activities in the rat tissue and brain region selectively. Life Sci 1992;50:1985-92.
8. Carrillo MC, Kanai S, Sato Y, Nokubo M, Ivy GO, Kitani K. The optimal dosage of (-)-deprenyl for increasing superoxide dismutase activity in several brain regions decreases with age in male Fischer 344 rats. Life Sci 1993;52:1925-34.
9. Chiueh CC, Huang SJ, Murphy DL. Supression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. J Neural Transm Suppl 1994;41:189-96.
10. Finnegan KT, Skratt JS, Irwin I, DeLanney LE, Langston JW. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 1990;184:119-26.
11. Freisleben HJ, Lehr F, Fuchs J. Lifespan of immunosuppressed NMRI-mice is increased by deprenyl. J Neural Transm Suppl 1994;41:231-6.
12. Gallagher IM, Clow A, Glover V. Long-term administration of (-)-deprenyl increases mortality in male Wistar rats. J Neural Transm Suppl 1998;52:315-20.
13. Gibson CJ. Inhibition of MAO-B, but not MAO-A blocks DSP-4 toxicity on central NE neurones. Eur J Pharmacol 1987;141:135-8.
14. Glover V, Gibb C, Sandier M. The role of MAO in MPTP toxicity - a review. J Neural Transm Suppl 1986;XX:65-76.
15. Haberle D, Szöko É, Magyar K. The influence of metabolism on the MAO-B inhibitory potency of selegiline. Curr Med Chem 2002;9:47-51.
16. Ham J, Babij C, Whitfield J, Pfarr CM, Lallemand D, Yaniv M, Rubin LL. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 1995;14:927-39.
17. Hársing LG, Magyar K, Tekes K, Vizi ES, Knoll J. Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition. Pol J Pharmacol Pharm 1979;31:297-307.
18. Heinonen EH, Myllyla V, Sotaniemi K, Lammintausta R, Salonen JS, Anttila M et al. Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 1989;126:93-9.
19. Hockenbery DM, Oltvai ZN, Xiao-Ming Y, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75:241-51.
20. Jarroff B, Vajda FJE. The current status of monoamine oxidase and its inhibitors. Med J Aust 1987;146:634-8.
21. Kitani K, Kanai S, Sato Y, Ohta M, Ivy GO, Carrillo MC. Chronic treatment of (-)-deprenyl prolongs the life span of male Fischer 344 rats: further evidence. Life Sci 1993;52:281-8.
22. Knoll J. The striatal dopamine dependence of life span in male rats: longevity study with (-)-deprenyl. Mech Age Dev 1988;46:237-62.
23. Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandier M, editors. Monoamine oxidases - new vistas advances in biochemistry and psychopharmacology, vol. 5. New York: Raven Press; 1972. p. 393-408.
24. Knoll J, Ecseri Z, Kelemen K, Nivel J, Knoll B. Phenylisopropylmethylpropinyl-amine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965;155:154-64.
25. Knoll J, Yen TT, Miklya I. Sexually low performing male rats die earlier than their high performing peers and (-)-deprenyl treatment eliminates this difference. Life Sci 1994;54:1047-57.
26. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80.
27. Langston JW, Langston EB, Irwin I. MPTP-induced Parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol Scand Suppl 1984;100:49-54.
28. Lees AL. Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-7.
29. Magyar K. Neuroprotective effect of deprenyl and p-fluordeprenyl. In: Proceedings of the Second Congress of Pan European Society of Neurology, Vienna; 1991. p. 26.
30. Magyar K. Pharmacology of monoamine oxidase type B inhibitors. In: Szelenyi B, Birkhauser I, editors. Inhibitors of monoamine oxidase. Verlag: Basel; 1993. p. 125-43.
31. Magyar K. The role of the metabolism of (-)-deprenyl in neuroprotection. In: Teelken AW, Korf J, editors. Proceedings of the 11th ESN Meeting. Neurochemistry; 1997. p. 303-8.
32. Magyar K, Vizi ES, Ecseri Z, Knoll J. Comparative pharmacological analysis of the optical isomers of phenyl-isopropylmethylpropinylamine (E-250). Acta Physiol Acad Sci Hung 1967;32(4):377-87.
33. Magyar K, Szende B, Lengyel J, Tekes K. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research. J Neural Transm Suppl 1996;48:29-43.
34. Magyar K, Szende B, Haberle D, Gaál J, Tarcali J. The neuroprotective and neuronal rescue effect of selegiline. In: Proceedings of the 18th European Winter Conference on Brain Research, Arc, 2000, vols. 7-14; France; 1998a. p. 42.
35. Magyar K, Szende B, Tarcali J, Szatmári I. The neuroprotective and neuronal rescue effects of(-)-deprenyl. J Neural Transm Suppl 1998b;52:109-23.
36. Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO. Maintenance on L-deprenyl prolongs life in aged male rats. Life Sci 1990;47:415-20.
37. Naoi M, Maruyama W, Kasamatsu T, Dostert P. Oxidation of N-methyl-(R)-salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines. J Neural Transm Suppl 1998;52:125-38.
38. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994;79:189-92.
39. Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A. Design and early clinical evaluation of selective inhibitors of monoamine oxidase. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:967-87.
40. Ricci A, Mancini M, Strocchi P, Bongrani, Bronzetti E. Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor L-deprenyl. Drugs Exp Clin Res 1992;VIII(5):163-71.
41. Ross SB, Renyi AL. On the long-lasting inhibitory effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on the active uptake of adrenaline. J Pharm Pharmacol 1976;28:458-9.
42. Sandler M. Monoamine oxidase inhibitor efficacy in depression and the cheese effect. Psychol Med 1981;11:455-8.
43. Schlingensiepen KH, Wolinik F, Kunst M, Sschlingensiepen R, Herdegen T, Brysch W. The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptations in vivo. Cell Mol Neurobiol 1994;14:487-505.
44. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Ann Neurol 2002;51(5):604-12.
45. 3H-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther 1969;165:78-86.
46. Szende B, Magyar K. Apoptotic and anti-apoptotic effect of deprenyl and desmetyl-deprenyl on human cell lines. In: Proceeding of the 8th Amine Oxidase Workshop, International Workshop on Monoamine Oxidases, Trace Amines, Neuroprotection and Neuronal Rescue, Balatonöszöd, Hungary; 1998. p. 17.
47. Szöko É, Kalász H, Magyar K. Metabolic transformation of deprenyl enantiomers in rats. Neurobiology 1999a;7(2): 247-54.
48. Szöko É, Kalász H, Magyar K. Biotransformation of deprenyl enantiomers. Eur J Drug Metab Pharmacokin 1999b;24:315-9.
49. Tatton WG. Agents that block mitochondrial initiation of apoptosis: a new opportunity for neuroprotection. In: Proceedings of the Satellite Symposium to the 3rd Congress of the European Federation of Neurological Societies on Selegiline in the Treatment of Neurodegenerative Diseases, Sevilla, Italy; 1998. p. 4.
50. Tatton WG, Chalmers-Redman RME. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neuro-degeneration. Neurology Suppl 1996;47(3):S171-83.
51. Tatton WG, Ju WYL, Holland DP, Tai CE, Kwan MM. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-4.
52. Tatton WG, Chalmers-Redman RME, Ju WYH, Waida J, Tatton NA. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J Neural Transm Suppl 1997;49:245-68.
53. The Parkinson Study Group: DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-60.
54. Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of L-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol 1993;243:241-8.
55. Yen TT, Knoll J. Extension of lifespan in mice treated with Dinh lang (Policias fruticosum L.) and (-)-deprenyl. Acta Physiol Hung 1992;79:119-24.
56. Youdim MBH, Finberg JPM. Monoamine oxidase B inhibition and the cheese effect. J Neural Transm Suppl 1987;25:27-33.
57. Yu PH, Davis BA, Fang J, Boulton AA. Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus. J Neurochem 1994;63:1820-8.